In this retrospective, single-center study, we aimed to clarify the possible survival benefit of additional resection of tissue demonstrating Met uptake beyond the contrast-enhanced region of tumors in patients with newly diagnosed, IDH1 wild-type GBM, and to evaluate neuropsychological outcomes following SupTR. This evidence concerns the gene IDH1 and glioblastoma.